ALK and non-small cell lung carcinoma: Metastatic squamous and non-squamous NSCLC patients, 18 years of age or older, with ECOG PS 0,1 and with adequate hematological and end-organ function. The population is defined through the common I/E criteria of IMpower130, 131 and 132 (limited to those criteria applicable retrospectively to observational data). To align the I/E criteria of the 3 trials, and to reflect the targeted population treated with 1L chemotherapy, patients with a sensitizing mutation in the EGFR gene or an ALK fusion oncogene were excluded